Sino Biopharmaceutical Ltd (FRA:SMZ1) Stock Price, Trades & News

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It has four main segments: oncology, liver, surgery/analgesics, and autoimmune/respiratory. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker for oncology after the Chinese government launched its volume-based procurement policy for the healthcare industry, whereby it reduces the price of its generic drugs in exchange for bulk procurement of its products. Oncology drugs make up its core innovative portfolio, while the other drugs are considered generic, which currently make up about half of its total revenue. Sino Biopharm competes with Hutchmed and Hengrui in the domestic oncology market, while it has a minimal presence in the global market.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	1.61
Equity-to-Asset	0.39
Debt-to-Equity	0.53
Debt-to-EBITDA	2
Interest Coverage	31.37
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.96	Distress Grey Safe
Beneish M-Score	-2.87	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.4
	3-Year EBITDA Growth Rate	9.5
	3-Year EPS without NRI Growth Rate	19
	3-Year FCF Growth Rate	20.1
	3-Year Book Growth Rate	1.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	4.14
	Future 3-5Y Total Revenue Growth Rate Estimate	9.94

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	67.55
	9-Day RSI	66
	14-Day RSI	62.75
	3-1 Month Momentum %	4.39
	6-1 Month Momentum %	-14.11
	12-1 Month Momentum %	-35.47

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.63
	Quick Ratio	1.56
	Cash Ratio	1.02
	Days Inventory	128.09
	Days Sales Outstanding	87.68
	Days Payable	131.22

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.82
	Dividend Payout Ratio	0.43
	3-Year Dividend Growth Rate	-2.1
	Forward Dividend Yield %	2.55
	5-Year Yield-on-Cost %	2.91
	3-Year Average Share Buyback Ratio	1.1
	Shareholder Yield %	-3.1

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	82.44
	Operating Margin %	30.14
	Net Margin %	7.37
	EBITDA Margin %	25.98
	FCF Margin %	21.77
	OCF Margin %	26.66
	ROE %	7.83
	ROA %	3.23
	ROIC %	15.29
	3-Year ROIIC %	9.04
	ROC (Joel Greenblatt) %	87.81
	ROCE %	16.95
	Years of Profitability over Past 10-Year	10
	Moat Score	6
	Tariff Resilience Score	5

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	36.47
	Forward PE Ratio	19.38
	PE Ratio without NRI	22.49
	Shiller PE Ratio	19.64
	Price-to-Owner-Earnings	18.3
	PS Ratio	2.69
	PB Ratio	2.69
	Price-to-Tangible-Book	3.56
	Price-to-Free-Cash-Flow	12.32
	Price-to-Operating-Cash-Flow	10.05
	EV-to-EBIT	10.48
	EV-to-Forward-EBIT	7.09
	EV-to-EBITDA	10.48
	EV-to-Forward-EBITDA	6.39
	EV-to-Revenue	2.72
	EV-to-Forward-Revenue	2.14
	EV-to-FCF	12.47
	Price-to-GF-Value	1.14
	Price-to-Projected-FCF	1.35
	Price-to-Median-PS-Value	0.85
	Price-to-Graham-Number	1.89
	Earnings Yield (Greenblatt) %	9.54
	FCF Yield %	8.24
	Forward Rate of Return (Yacktman) %	-2.08

Financials (Next Earnings Date:2027-02-19 Est.)

Annual Quarterly TTM

FRA:SMZ1's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Sino Biopharmaceutical Ltd Executives

Details

GF Value™: €0.53

FRA:SMZ1

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with SMZ1. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	4,219.894
	EPS (TTM) (€)	0.017
	Beta	0.6393
	3-Year Sharpe Ratio	0.33
	3-Year Sortino Ratio	0.6
	Volatility %	29.98
	14-Day RSI	62.75
	14-Day ATR (€)	0.014961
	20-Day SMA (€)	0.554645
	12-1 Month Momentum %	-35.47
	52-Week Range (€)	0.4677 - 0.9926
	Shares Outstanding (Mil)	17,818.95

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Sino Biopharmaceutical Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Sino Biopharmaceutical Ltd Stock Events

Financials Calendars

Event	Date	Price (€)
HKD 0.070000 Cash Dividend	2026-09-01	In 4 days
Second quarter earnings results for 2026	2026-08-19	0.51 (+0.00%)
HKD 0.050000 Cash Dividend	2026-06-24	0.49 (+0.00%)
General meeting for 2025	2026-06-17 11:00	0.52 (+4.00%)
Annual report for 2025	2026-04-29	0.58 (+0.00%)
HKD 0.050000 Cash Dividend	2025-08-29	0.86 (-0.99%)
Second quarter earnings results for 2025	2025-08-18	0.84 (+0.07%)
HKD 0.040000 Cash Dividend	2025-06-16	0.60 (+1.58%)
General meeting for 2024	2025-06-10 15:00	0.52 (+0.00%)
Annual report for 2024	2025-04-29	0.43 (+0.00%)

Show

Entries

Sino Biopharmaceutical Ltd Frequently Asked Questions

What is Sino Biopharmaceutical Ltd(FRA:SMZ1)'s stock price today?

The current price of FRA:SMZ1 is €0.61. The 52 week high of FRA:SMZ1 is €0.99 and 52 week low is €0.47.

When is next earnings date of Sino Biopharmaceutical Ltd(FRA:SMZ1)?

The next earnings date of Sino Biopharmaceutical Ltd(FRA:SMZ1) is 2027-02-19 Est..

Does Sino Biopharmaceutical Ltd(FRA:SMZ1) pay dividends? If so, how much?

The Dividend Yield % of Sino Biopharmaceutical Ltd(FRA:SMZ1) is 1.82% (As of Today), Highest Dividend Payout Ratio of Sino Biopharmaceutical Ltd(FRA:SMZ1) was 0.75. The lowest was 0.05. And the median was 0.27. The Forward Dividend Yield % of Sino Biopharmaceutical Ltd(FRA:SMZ1) is 2.55%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	Sino Biopharm (1177.HK) Announces 2025 Annual Results	2026-03-26
	Sino Biopharm (1177.HK) Announces 2025 Interim Results	2025-08-18
	Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial	2025-05-05
	Sino Biopharm (1177.HK) Announces 2024 Annual Results	2025-03-20
	Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results	2024-08-13
	Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China	2021-08-05
	Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics	2020-01-13
	Akeso, Inc. Completed Series-D Private Financing for close to US$150 Million	2019-11-09

10/Page

Articles on Sino Biopharmaceutical Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.